JP2010502638A5 - - Google Patents

Info

Publication number

JP2010502638A5

JP2010502638A5 JP2009526850A JP2009526850A JP2010502638A5 JP 2010502638 A5 JP2010502638 A5 JP 2010502638A5 JP 2009526850 A JP2009526850 A JP 2009526850A JP 2009526850 A JP2009526850 A JP 2009526850A JP 2010502638 A5 JP2010502638 A5 JP 2010502638A5

Authority

JP

Japan

Prior art keywords

patient

radiation therapy

composition

agonist

administration

Prior art date

2007-08-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 238000001959 radiotherapy Methods 0.000 claims description 58
• 239000000556 agonist Substances 0.000 claims description 41
• 239000000203 mixture Substances 0.000 claims description 34
• 206010028980 Neoplasm Diseases 0.000 claims description 24
• 108050009340 Endothelin Proteins 0.000 claims description 21
• 102000002045 Endothelin Human genes 0.000 claims description 21
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 21
• 108010091477 IRL 1620 Proteins 0.000 claims description 16
• DXPHNGAMYPPTBJ-TZMIJSMNSA-N irl 1620 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CCC(O)=O)C(C)C)C1=CN=CN1 DXPHNGAMYPPTBJ-TZMIJSMNSA-N 0.000 claims description 16
• KIYSPBOGUDIMPC-SCGUGKIPSA-N 4-ala-endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)OC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)OC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC)C(C)C)C1C=NC=N1 KIYSPBOGUDIMPC-SCGUGKIPSA-N 0.000 claims description 8
• 101710205037 Sarafotoxin Proteins 0.000 claims description 8
• 150000001875 compounds Chemical class 0.000 claims description 8
• 230000005855 radiation Effects 0.000 claims description 8
• 206010025323 Lymphomas Diseases 0.000 claims description 7
• 238000002648 combination therapy Methods 0.000 claims description 7
• 230000000637 radiosensitizating effect Effects 0.000 claims description 6
• 201000011510 cancer Diseases 0.000 claims description 5
• 239000003795 chemical substances by application Substances 0.000 claims description 5
• 238000001361 intraarterial administration Methods 0.000 claims description 4
• 230000002601 intratumoral effect Effects 0.000 claims description 4
• 238000001990 intravenous administration Methods 0.000 claims description 4
• 239000002534 radiation-sensitizing agent Substances 0.000 claims description 4
• 230000001235 sensitizing effect Effects 0.000 claims description 4
• 208000026310 Breast neoplasm Diseases 0.000 claims description 3
• 206010019695 Hepatic neoplasm Diseases 0.000 claims description 3
• 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
• 208000029742 colonic neoplasm Diseases 0.000 claims description 3
• 230000003325 follicular Effects 0.000 claims description 3
• 208000014018 liver neoplasm Diseases 0.000 claims description 3
• 201000001441 melanoma Diseases 0.000 claims description 3
• 206010027191 meningioma Diseases 0.000 claims description 3
• 208000023958 prostate neoplasm Diseases 0.000 claims description 3
• 230000009885 systemic effect Effects 0.000 claims description 3
• 206010006187 Breast cancer Diseases 0.000 claims description 2
• 239000000654 additive Substances 0.000 claims description 2
• 230000000996 additive effect Effects 0.000 claims description 2
• 230000036770 blood supply Effects 0.000 claims description 2
• 231100000433 cytotoxic Toxicity 0.000 claims description 2
• 230000001472 cytotoxic effect Effects 0.000 claims description 2
• 230000000694 effects Effects 0.000 claims description 2
• 230000002195 synergetic effect Effects 0.000 claims description 2
• -1 bets Substances 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1
• 238000011200 topical administration Methods 0.000 claims 1
• 238000000034 method Methods 0.000 description 11
• 238000011292 agonist therapy Methods 0.000 description 1